68 well-known pharmaceutical companies executive changes Multi-factor overlay of pharmaceutical perities under pressure

Pharmaceutical Network July 2nd, the first half of 2020, the domestic listed pharmaceutical companies executive changes intensive1.68listed pharmaceutical companies, executive adjustmentAccording to China Net Finance, 2019 revenue of more than 100 million yuan of listed pharmaceutical companies, about 68 enterprises have adjusted the senior management level, involving China Pharmaceuticals, Fosun Pharma, Renfu Pharmaceuticals, Haizheng Pharmaceuticals, Ha Pharmaceuticals shares, China Resources Shuanghe and other well-known pharmaceutical companiesAccording to the previous Cypress Blue incomplete statistics, if not listed pharmaceutical companies and revenue as the boundary, in the first three months of 2020 alone, the pharmaceutical industry has more than 60 executives left, in April alone, 18 pharmaceutical executives offered to resign and be approved - including Haizheng Pharmaceuticals senior vice president Wang Haibin, Ted Pharmaceuticals President Kong Tai, Renfu Pharmaceuticals Chairman Wang Xuehai, Fosun Pharmaceuticalvicevice President Dai Kun and so onAccording to Seberlan combing, the reasons for the resignation of these pharmaceutical executives mainly include work reasons, personal reasons, term expiration, job division adjustment, among which mainly for personal reasonsAmong them, Fosun Pharmaceuticals, Northeast Pharmaceuticals, Jiuzhitang, Dongcheng Pharmaceuticals, Jiangsu Wuzhong, Lisheng Pharmaceuticals 6 pharmaceutical companies executives left the number of 4 or more peopleAmong them, the vice president ship of Fosun Pharmaceuticals and the position of deputy general manager of Northeast Pharmaceuticals change most frequently - according to incomplete statistics, in the past half year, Fosun Pharmaceuticals' five senior executives left in succession;In addition, across different positions, the number of senior executives who left in the first half of this year reached six - in January, Yang Lianmin and Gao Jinyan resigned as deputy general managers of Jiuzhitang;In addition to Zhao Zhong, Jiangsu Province, who applied to resign as chairman and director from retirement age, three other senior executives resigned for personal reasonsLooking at not strictly to the first half of the demarcation situation, the more frequent changes in senior management of listed pharmaceutical companies have Huaren Pharmaceuticals, Ha Pharmaceutical Group, etc- according to the 2019 annual report of Ha Pharmaceuticals, as of March 31, 2020, Liu Gangmin, Wu Zhijun, Zhou Xing, Wei Shuangying 4 deputy general managers have left, including Wu Zhijun, the reasons for leaving are "personal reasons", including Liu Helper's time in office is only 19 days2multiple factors superimposed,pharmaceuticalunder pressure
Beijing Dingchen Pharmaceutical Management Consulting Center founder Shi Lichen on the above phenomenon to Seiberlan said that compared with the same period in previous years, the pharmaceutical executives change more frequently this year 　　He believes that the main reasons for the above phenomenon are changes in the policy environment and market environment - in the 4-7 band procurement, two-vote system, tender
price reduction, medical insurance control fees and consistency evaluation of the role of the new round of national health reform policy, pharmaceutical companies are facing greater policy pressure, market competition has become more intense Under the pressure of policy and market, pharmaceutical enterprises still need performance , but many pharmaceutical executives management style and operational thinking has not yet timely adapted to the new policy and market environment, but also continue to follow its original thinking and management methods, when once the performance is not completed, the frequent departure of senior executives is easy to occur 　　Shi Lichen believes that the relationship between the development of pharmaceutical companies and the decision-making level of enterprises is very close, in peacetime, senior executives can determine the development direction of pharmaceutical companies to a certain extent, in times of change, the decision-making ability of senior executives and the ability to recognize the market and policy, to a certain extent, determines the survival of pharmaceutical companies 　　However, Shi Lichen also said that it is necessary to see that the performance of pharmaceutical enterprises is not only by professional managers can be changed, some pharmaceutical companies themselves operating efficiency and management systems have serious problems, at this time, professional managers alone are difficult to improve, and even say that no matter how change managers may not be able to reverse their bad operating situation 　　In addition to macro factors, Mr Shrichen argues that the high variability of pharmaceutical executives as professional managers themselves has also led to frequent departures, which he says are not closee enough to pharmaceutical companies, unlike shareholder-to-drug relationships Departures are easily occurring when executives are unable to meet the needs of pharmaceutical companies or when pharmaceutical companies are unable to provide the pay and career development opportunities that executives expect 　　From the statistics can be seen from the statistics, the high-level departure of senior executives of pharmaceutical enterprises mainly to chemical pharmaceutical enterprises, involving fewer Chinese medicine enterprises - Shi Lichen analysis pointed out that this and the first half of the chemical pharmaceutical enterprises and Chinese medicine enterprises face different developments related 　　Under the outbreak, most of the country's hospitals affected to varying degrees, hospital outpatient spending, inpatient volume during the outbreak decline, many chemical enterprises production, logistics and distribution, marketing work is limited, production and operation affected But the outbreak has made the Chinese medicine enterprises ushered in the opportunity to glow fever, many Chinese medicine enterprises are good performance 　　Further speaking of the policy affecting chemical pharmaceutical enterprises, the volume procurement bear the brunt - Shrichen predicted that the impact of tape procurement on pharmaceutical companies is continuous and high-pressure, only all chemical generics of the band procurement is done, the volume of procurement work can be terminated 　　In general, the cost of health care control is a normal process, the corresponding series of policies and market pressure caused by personnel changes will continue It must be noted that, in addition to senior executives, frequent adjustments are also a larger volume of middle-level and grass-roots pharmaceutical company personnel, some of them actively leave their posts, some passive layoffs Source: China